Patents Assigned to Prana Biotechnology Limited
-
Publication number: 20210230159Abstract: The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.Type: ApplicationFiled: April 7, 2021Publication date: July 29, 2021Applicant: Prana Biotechnology LimitedInventors: Penelope Jane Huggins, Jack Gordon Parsons, Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Antony Vincent Robinson
-
Patent number: 11008319Abstract: The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.Type: GrantFiled: June 24, 2020Date of Patent: May 18, 2021Assignee: Prana Biotechnology LimitedInventors: Penelope Jane Huggins, Jack Gordon Parsons, Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Antony Vincent Robinson
-
Publication number: 20200317670Abstract: The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.Type: ApplicationFiled: June 24, 2020Publication date: October 8, 2020Applicant: Prana Biotechnology LimitedInventors: Penelope Jane Huggins, Jack Gordon Parsons, Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Antony Vincent Robinson
-
Patent number: 10738050Abstract: The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.Type: GrantFiled: May 10, 2019Date of Patent: August 11, 2020Assignee: Prana Biotechnology LimitedInventors: Penelope Jane Huggins, Jack Gordon Parsons, Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Antony Vincent Robinson
-
Patent number: 10287285Abstract: The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.Type: GrantFiled: December 2, 2015Date of Patent: May 14, 2019Assignee: Prana Biotechnology LimitedInventors: Penelope Jane Huggins, Jack Gordon Parsons, Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Antony Vincent Robinson
-
Patent number: 9302993Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: GrantFiled: October 9, 2014Date of Patent: April 5, 2016Assignee: PRANA BIOTECHNOLOGY LIMITEDInventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
-
Publication number: 20150359796Abstract: The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD).Type: ApplicationFiled: August 21, 2015Publication date: December 17, 2015Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Penelope Jane Huggins, Jack Gordon Parsons
-
Publication number: 20150335635Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: ApplicationFiled: August 5, 2015Publication date: November 26, 2015Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Kevin Jeffrey BARNHAM, Elisabeth Colette Louise GAUTIER, Gaik Beng KOK, Guy KRIPPNER
-
Patent number: 9169211Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: GrantFiled: October 9, 2014Date of Patent: October 27, 2015Assignee: PRANA BIOTECHNOLOGY LIMITEDInventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
-
Patent number: 9145375Abstract: The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I).Type: GrantFiled: October 7, 2014Date of Patent: September 29, 2015Assignee: PRANA BIOTECHNOLOGY LIMITEDInventors: Penelope Jane Huggins, Jack Gordon Parsons
-
Publication number: 20150094334Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: ApplicationFiled: October 9, 2014Publication date: April 2, 2015Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Kevin Jeffrey BARNHAM, Elisabeth Colette Louise GAUTIER, Gaik Beng KOK, Guy KRIPPNER
-
Patent number: 8975278Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: GrantFiled: September 19, 2007Date of Patent: March 10, 2015Assignee: Prana Biotechnology LimitedInventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
-
Publication number: 20150025072Abstract: The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I).Type: ApplicationFiled: October 7, 2014Publication date: January 22, 2015Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Penelope Jane HUGGINS, Jack Gordon PARSONS
-
Publication number: 20150025108Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: ApplicationFiled: October 9, 2014Publication date: January 22, 2015Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Kevin Jeffrey BARNHAM, Elisabeth Colette Louise GAUTIER, Gaik Beng KOK, Guy KRIPPNER
-
Patent number: 8889695Abstract: The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I).Type: GrantFiled: December 23, 2009Date of Patent: November 18, 2014Assignee: Prana Biotechnology LimitedInventors: Penelope Jane Huggins, Jack Gordon Parsons
-
Publication number: 20140088122Abstract: The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.Type: ApplicationFiled: November 22, 2013Publication date: March 27, 2014Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Penelope Jane HUGGINS, Gaik Being KOK
-
Patent number: 8318171Abstract: This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.Type: GrantFiled: May 14, 2009Date of Patent: November 27, 2012Assignees: Prana Biotechnology Limited, The General Hospital CorporationInventors: Ashley Bush, Robert Cherny
-
Patent number: 8163760Abstract: The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumors and related conditions. The therapeutic agent comprises two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8.Type: GrantFiled: June 22, 2007Date of Patent: April 24, 2012Assignee: Prana Biotechnology LimitedInventors: Ashley Bush, Penelope Jane Huggins, Jack Gordon Parsons, Gaik Beng Kok, Vijaya Kenche
-
Publication number: 20120040980Abstract: The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I).Type: ApplicationFiled: December 23, 2009Publication date: February 16, 2012Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Penelope Jane Huggins, Jack Gordon Parsons
-
Publication number: 20110071167Abstract: The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.Type: ApplicationFiled: November 23, 2010Publication date: March 24, 2011Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Ashley BUSH, Colin Louis MASTERS, Penelope Jane HUGGINS, Jack Gordon PARSONS, Gaik Beng KOK, Vijaya KENCHE, Mariana EL SOUS